A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered BI 409306 During a 52-week Treatment Period as an Early Intervention in Patients With Attenuated Psychosis Syndrome.
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs BI 409306 (Primary)
- Indications Psychotic disorders
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 29 May 2019 Planned End Date changed from 28 May 2021 to 25 May 2022.
- 29 May 2019 Planned primary completion date changed from 8 Mar 2021 to 27 Apr 2022.
- 02 Oct 2017 Status changed from not yet recruiting to recruiting.